Increasing diversity and inclusion in nephrology clinical trials

Racial and ethnic minoritized populations are underrepresented in clinical trials in nephrology, but overrepresented in adverse kidney disease outcomes. Targeted enrolment, revision of problematic policies, inclusion of minoritized populations in trial planning, and language-, race- and ethnicity-co...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Nephrology Vol. 19; no. 10; pp. 627 - 628
Main Authors Young, Bessie A, Rosas, Sylvia E
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.10.2023
Subjects
Asian Americans
Clinical trials
Coronaviruses
COVID-19
Diabetes
Ethnicity
Funding
Hemodialysis
Hispanic Americans
Hospitalization
Human subjects
Infections
Kidney diseases
Meta-analysis
Minority & ethnic groups
Multiculturalism & pluralism
Nephrology
Patients
Public health
Race
Systematic review
Transplants & implants
Online AccessGet full text

Cover

More Information
Summary:Racial and ethnic minoritized populations are underrepresented in clinical trials in nephrology, but overrepresented in adverse kidney disease outcomes. Targeted enrolment, revision of problematic policies, inclusion of minoritized populations in trial planning, and language-, race- and ethnicity-concordant investigative teams can improve representation in clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1759-5061
1759-507X
DOI:10.1038/s41581-023-00756-3